Clinical Trial Update: Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Copanlisib in combination with Fulvestrant in ER+/PR+ cancers with PI3K/PTEN alterations was terminated, with trial results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Ovarian Cancer

Drugs mentioned

• Copanlisib (copanlisib)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Endometrial Cancer, Ovarian Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-07-11